CTNNB1 and melanoma: The first cohort (TCGA SKCM) included patients with stage II-IV melanoma, was not enriched for APC/CTNNB1 mutations (approximately 11.5%, prospective analysis), and historically preceded FDA approval of PD1 inhibitors.